I thank hon. Members, who have all spoken passionately. I will try very briefly to address some of their points.
The hon. Member for North Down (Stephen Farry) asked about the impact of CJEU provision on Northern Ireland access to the EU single market. When he raised the point, I reiterated the importance of cross-community consent; I should also reassure him and the Committee that we want and intend to retain elements of the protocol that are working and preserve north-south trade and co-operation. As the Prime Minister has said, we want to fix it, not nix it. The Bill just makes targeted changes to address key concerns and restore balance.
The hon. Member for Strangford (Jim Shannon) raised some technical questions about pharmaceuticals; I will write to him about them.
The right hon. Member for Leeds Central (Hilary Benn) referred to clause 18, which I assure him is genuinely less exciting than some might think. Normally, as he knows, the lawfulness of Ministers’ non-legislative actions can be taken for granted or implied. The Bill is slightly unusual in that it clarifies how new domestic obligations replace prior domestic obligations that stem from international obligations. Those international obligations are currently implemented automatically by section 7A of the European Union (Withdrawal) Act 2018. That conduit pipe currently constrains—and could cause confusion in future as to —how Ministers can act in support of the Bill. Clause 18 will remove that potential confusion.
The hon. Member for Belfast South (Claire Hanna) juxtaposed Northern Ireland with Cyprus. I do not need to say to anyone on the Committee, particularly anyone from anywhere on the island of Ireland, that the history and geography of Northern Ireland is vastly different from that of Cyprus, so it is clear that different issues might arise from the remit of the CJEU. On that note, I recommend that the clauses stand part of the Bill.